Sec. 51. (a) As used in this section, "advisory committee" refers to the mental health Medicaid quality advisory committee established by subsection (b).
(b) The mental health Medicaid quality advisory committee is established. The advisory committee consists of the following members:
(1) The director of the office or the director's designee, who shall serve as chairperson of the advisory committee.
(2) The director of the division of mental health and addiction or the director's designee.
(3) A representative of a statewide mental health advocacy organization.
(4) A representative of a statewide mental health provider organization.
(5) A representative from a managed care organization that participates in the state's Medicaid program.
(6) A member with expertise in psychiatric research representing an academic institution.
(7) A pharmacist licensed under IC 25-26.
(8) The commissioner of the department of correction or the commissioner's designee.
The governor shall make the appointments for a term of four (4) years under subdivisions (3) through (7) and fill any vacancy on the advisory committee.
(c) The office shall staff the advisory committee. The expenses of the advisory committee shall be paid by the office.
(d) Each member of the advisory committee who is not a state employee is entitled to the minimum salary per diem provided by IC 4-10-11-2.1(b). The member is also entitled to reimbursement for traveling expenses as provided under IC 4-13-1-4 and other expenses actually incurred in connection with the member's duties as provided in the state policies and procedures established by the Indiana department of administration and approved by the budget agency.
(e) Each member of the advisory committee who is a state employee is entitled to reimbursement for traveling expenses as provided under IC 4-13-1-4 and other expenses actually incurred in connection with the member's duties as provided in the state policies and procedures established by the Indiana department of administration and approved by the budget agency.
(f) The affirmative votes of a majority of the voting members appointed to the advisory committee are required by the advisory committee to take action on any measure.
(g) The advisory committee shall advise the office and make recommendations concerning the clinical use of mental health and addiction medications, including the implementation of IC 12-15-35.5-7(c), and consider the following:
(1) Peer reviewed medical literature.
(2) Observational studies.
(3) Health economic studies.
(4) Input from physicians and patients.
(5) Any other information determined by the advisory committee to be appropriate.
(h) The office shall report recommendations made by the advisory committee to the drug utilization review board established by section 19 of this chapter.
As added by P.L.36-2009, SEC.2. Amended by P.L.185-2013, SEC.1; P.L.205-2013, SEC.207; P.L.2-2014, SEC.65; P.L.53-2014, SEC.107; P.L.130-2018, SEC.50.
Structure Indiana Code
Chapter 35. Drug Utilization Review
12-15-35-1. "Appropriate and Medically Necessary" Defined
12-15-35-3. "Compendia" Defined
12-15-35-4. "Counseling" Defined
12-15-35-4.5. "Covered Outpatient Drug" Defined
12-15-35-5. "Criteria" Defined
12-15-35-6. "Drug-Disease Contraindication" Defined
12-15-35-7. "Drug-Drug Interaction" Defined
12-15-35-8. "Drug Utilization Review" or "Dur" Defined
12-15-35-9. "Intervention" Defined
12-15-35-10. "Overutilization or Underutilization" Defined
12-15-35-11. "Pharmacist" Defined
12-15-35-12. "Physician" Defined
12-15-35-13. "Prospective Dur" Defined
12-15-35-14. "Retrospective Dur" Defined
12-15-35-15. "Standards" Defined
12-15-35-17. "Therapeutic Appropriateness" Defined
12-15-35-17.5. "Therapeutic Classification" or "Therapeutic Category" Defined
12-15-35-18. "Therapeutic Duplication" Defined
12-15-35-18.5. Application of Chapter
12-15-35-18.7. Formulary Requirements
12-15-35-19. Drug Utilization Review Board; Establishment
12-15-35-20. Membership of Board
12-15-35-20.1. Conflicts of Interest
12-15-35-20.5. Therapeutics Committee Established; Members; Limitations; Terms; Votes; Meetings
12-15-35-21. Board; Appointment; Term
12-15-35-22. Qualifications of Board Members
12-15-35-23. Physician Appointments; Geographic Balance
12-15-35-24. Reappointment of Members
12-15-35-25. Chairman; Compensation; Expenses
12-15-35-27. Retrospective and Prospective Dur Program Responsibility
12-15-35-28. Duties of the Board; Preferred Drug List; Report
12-15-35-28.5. Therapeutics Committee Duties
12-15-35-29. Quorum; Majority Vote on Dur Criteria and Standards for Prescribing
12-15-35-30. Local Practices; Monitoring
12-15-35-31. Intervention; Approval; Requisites
12-15-35-32.1. Annual Report Contents
12-15-35-34. Confidential Identifying Information; Release of Cumulative Nonidentifying Information
12-15-35-35. Prior Approval Program for Outpatient Drugs; Standards
12-15-35-36. Advisory Committees
12-15-35-37. Medicaid State Plan; Inclusion of Retrospective and Prospective Dur Program
12-15-35-38. Dur Program Guidelines and Procedures
12-15-35-39. Retrospective Dur Requisites
12-15-35-40. Prospective Dur Requisites
12-15-35-41. Board Activities Under Ic 34-30-15
12-15-35-43. Confidentiality; Pharmacist Data and Information
12-15-35-44. Confidentiality; Violations; Penalty
12-15-35-45. Outpatient Drug Formulary; Requirements
12-15-35-46. Review of Proposed Formulary
12-15-35-47. Review of Changes to Formulary
12-15-35-48. Board Review of Managed Care Organization Prescription Drug Program
12-15-35-49. Information Provided by Office
12-15-35-50. Maximum Allowable Cost Schedule for Drugs; Pharmacy Participation in Medicaid Program